Two approved drug families compared directly in SURMOUNT-5.
Bottom line: SURMOUNT-5 directly compared the two drugs over 72 weeks. Mean weight decreased by 20.2% with tirzepatide and 13.7% with semaglutide. The older 22.5% and 15% figures came from separate trials and are not a fair head-to-head comparison. [4]
| Semaglutide | Tirzepatide | |
|---|---|---|
| Head-to-head result | Mean weight decreased by 13.7% at 72 weeks. [4] | Mean weight decreased by 20.2% at 72 weeks. [4] |
| Products | Ozempic, Wegovy, Wegovy HD and Rybelsus have different labeled uses and instructions. [1,2] | Mounjaro and Zepbound have different labeled uses and product instructions. [5] |
| Compounded versions | Not automatically identical or interchangeable with an approved brand. [3] | Not automatically identical or interchangeable with an approved brand. [6] |
summary: SURMOUNT-5 directly compared the two drugs over 72 weeks. Mean weight decreased by 20.2% with tirzepatide and 13.7% with semaglutide. The older 22.5% and 15% figures came from separate trials and are not a fair head-to-head comparison. [4]
trials: []
No. It compares evidence and status. Use the exact approved label and prescriber plan, or a registered clinical-trial protocol if you are enrolled.
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
